NIZZARDO, MONICA
NIZZARDO, MONICA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model
2026 E. Pagliari, A. Anastasia, F. Bellandi, M. Garbellini, J. Ongaro, M. Taiana, G.P. Comi, L. Ottoboni, J.A. Sierra-Delgado, S. Likhite, K.C. Meyer, M. Nizzardo, S.P. Corti
iPSC-derived human cortical organoids display profound alterations of cellular homeostasis following SARS-CoV-2 infection and Spike protein exposure
2025 G. Cappelletti, L. Brambilla, S. Strizzi, F. Limanaqi, V. Melzi, M. Rizzuti, M. Nizzardo, I. Saulle, D. Trabattoni, S. Corti, M. Clerici, M. Biasin
Targeting STMN2 for neuroprotection and neuromuscular recovery in Spinal Muscular Atrophy: evidence from in vitro and in vivo SMA models
2025 E. Pagliari, M. Taiana, P. Manzini, L. Sali, L. Quetti, L. Bertolasi, S. Oldoni, V. Melzi, G. Comi, S. Corti, M. Nizzardo, F. Rizzo
Generation of two hiPSC lines (UMILi027-A and UMILi028-A) from early and late-onset Congenital Central hypoventilation Syndrome (CCHS) patients carrying a polyalanine expansion mutation in the PHOX2B gene
2022 A.L. Cuadros Gamboa, R. Benfante, M. Nizzardo, T. Bachetti, P. Pelucchi, V. Melzi, C. Arzilli, M. Peruzzi, R.A. Reinbold, S. Cardani, A. Morrone, R. Guerrini, I. Zucchi, S. Corti, I. Ceccherini, R. Piumelli, N. Nassi, S. Di Lascio, D. Fornasari
Targeting PTB for Glia‐to‐Neuron Reprogramming In Vitro and In Vivo for Therapeutic Development in Neurological Diseases
2022 M. Contardo, R. De Gioia, D. Gagliardi, G.P. Comi, L. Ottoboni, M. Nizzardo, S. Corti
Stathmins and Motor Neuron Diseases: Pathophysiology and Therapeutic Targets
2022 D. Gagliardi, E. Pagliari, M. Meneri, V. Melzi, F. Rizzo, G.P. Comi, S.P. Corti, M.M. Taiana, M. Nizzardo
Molecular analysis of SMARD1 patient-derived cells demonstrates that nonsense-mediated mRNA decay is impaired
2022 M. Taiana, A. Govoni, S. Salani, N. Kleinschmidt, N. Galli, M. Saladini, S.B. Ghezzi, V. Melzi, M. Bersani, R. Del Bo, O. Muehlemann, E. Bertini, V. Sansone, E. Albamonte, S. Messina, F. Mari, E. Cesaroni, L. Porfiri, F.D. Tiziano, G.L. Vita, M. Sframeli, C. Bonanno, N. Bresolin, G. Comi, S. Corti, M. Nizzardo
Morpholino oligomers ameliorates pathological hallmarks in C9orf72 cellular lines and mice
2021 M. Bersani, D. Gagliardi, M. Taiana, F. Biella, M. Nizzardo, S. Corti
C9orf72 ALS Human Neural Organoids for the Development of New Therapeutics and Disease Modeling
2021 G. Costamagna, F. Biella, I. Faravelli, M. Nizzardo, R. Brusa, G.P. Comi, N. Bresolin, S.P. Corti
Human spinal cord-like organoids to model C9ORF72 ALS and test new therapies in vitro
2021 G. Costamagna, N. Galli, M. Rizzuti, B. Frizzi, F. Biella, M. Taiana, S. Ghezzi, I. Faravelli, G.P. Comi, M. Nizzardo, S. Corti
Cell-penetrating peptide-conjugated Morpholino rescues SMA in a symptomatic preclinical model
2021 M. Bersani, M. Rizzuti, E. Pagliari, M. Garbellini, D. Saccomanno, H.M. Moulton, N. Bresolin, G.P. Comi, S. Corti, M. Nizzardo
Dysregulation of Muscle-Specific MicroRNAs as Common Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from Animal Models and Human Patients
2021 C. Malacarne, M. Galbiati, E. Giagnorio, P. Cavalcante, F. Salerno, F. Andreetta, C. Cagnoli, M. Taiana, M. Nizzardo, S. Corti, V. Pensato, A. Venerando, C. Gellera, S. Fenu, D. Pareyson, R. Masson, L. Maggi, E. Dalla Bella, G. Lauria, R. Mantegazza, P. Bernasconi, A. Poletti, S. Bonanno, S. Marcuzzo
Current understanding of and emerging treatment options for spinal muscular atrophy with respiratory distress type 1 (SMARD1)
2020 M.G.L. Perego, N. Galli, M. Nizzardo, A. Govoni, M. Taiana, N. Bresolin, G.P. Comi, S. Corti
Evaluation of Morpholino oligomers therapeutic efficacy in C9orf72 ALS iPSC-derived lines
2020 M. Bersani, M. Taiana, F. Biella, M. Nizzardo, S. Ghezzi, N. Bresolin, G.P. Comi, S. Corti
Spinal muscular atrophy with respiratory distress type 1: Clinical phenotypes, molecular pathogenesis and therapeutic insights
2020 M. Saladini, M. Nizzardo, A. Govoni, M. Taiana, N. Bresolin, G.P. Comi, S. Corti
Animal Models of CMT2A: State-of-art and Therapeutic Implications
2020 R. De Gioia, G. Citterio, E. Abati, M. Nizzardo, N. Bresolin, G.P. Comi, S. Corti, F. Rizzo
Cell Penetrating peptide-conjugated Morpholino rescues SMA in a symptomatic preclinical model
2020 E. Pagliari, M. Bersani, M. Rizzuti, A. Bordoni, D. Saccomanno, H.M. Moulton, N. Bresolin, G.P. Comi, S. Corti, M. Nizzardo
Neural stem cell transplantation for neurodegenerative diseases
2020 R. De Gioia, F. Biella, G. Citterio, F. Rizzo, E. Abati, M. Nizzardo, N. Bresolin, G.P. Comi, S. Corti
Optimization of AAV9 gene therapy for Spinal Muscular Atrophy with respiratory distress Type 1 using in vivo disease models
2020 E. Pagliari, P. Rinchetti, N. Galli, S. Ghezzi, M. Taiana, G. Comi, S. Corti, M. Nizzardo
CPPs-conjugated antisense nucleotides : a new therapeutic strategy for Spinal Muscular Atrophy symptomatic patients
2020 E. Pagliari, M. Bersani, M. Rizzuti, A. Bordoni, D. Saccomanno, N. Bresolin, G. Comi, S. Corti, M. Nizzardo